VViva In Vitro Diagnostics
Viva In Vitro Diagnostics is a Spanish biotech founded in 2021 as the first spin-off of IMIB (Instituto Murciano de Investigación Biosanitaria), specialised in immunological medicine and precision diagnostics based on functional activation of the NLRP3 inflammasome. Its lead technology, VIVA-ELISA® (and the Viva Sepscare® prototype), detects ASC-Specks to identify and stratify critically ill patients, starting with sepsis and expanding toward autoimmune disease, neuroinflammation and oncology. It has raised over €5.7M combining private rounds and public funding, including €2.5M non-dilutive from the EIC Transition programme (selected among 40 most disruptive European companies) plus ENISA, NEOTEC and CDTI support. It is headquartered in Murcia.
Founders
Global models 5
I
C
I
A
PIn the same niche 48 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 10
Open as list →
V
W
FFunding rounds 4
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-09 | Seed (estimated) | €1.3M |
Murcia Emprende SCR
+6 more
|
| 2023-02-23 | Seed (estimated) | €880K |
Lead not disclosed
+1 more
|
| 2022-11-09 | Pre-seed | — |
Lead not disclosed
+1 more
|
| 2022-06-07 | Pre-seed | €275K | Vincle Capital |